Status:
COMPLETED
High Density Mapping in Brugada Syndrome
Lead Sponsor:
Universitair Ziekenhuis Brussel
Conditions:
Brugada Syndrome
Eligibility:
All Genders
15+ years
Brief Summary
The current study has the following objectives: 1. To characterize the changes in amplitude and duration of epicardial right ventricular outflow tract electrograms captured through a multipolar mappi...
Detailed Description
BACKGROUND PATHOGENESIS IN BRUGADA SYNDROME The pathophysiological basis of Brugada syndrome (BrS) is controversial. Two are the main theories which explain the electrocardiographic findings localized...
Eligibility Criteria
Inclusion
- high density epicardial EAM performed with the multipolar mapping catheter Advisor™ HD-Grid Mapping Catheter, (Abbott Labs, Abbott Park, IL, USA) in association with the EnSite Precision™ Cardiac Mapping System, (Abbott Labs, Abbott Park, IL, USA);
- epicardial EAM performed before and after ajmaline infusion at standard protocol (1 mg/kg in 5 minutes);
- ECGI activation map performed before and after ajmaline and concomitant with invasive EAM acquisition.
Exclusion
- Spontaneous BrS type I pattern ECG during EAM acquisition. Patients were included if they had a history of spontaneous BrS type I;
- other diagnosis different from BrS syndrome or overlap syndrome diagnosis by means of genetic analysis, transthoracic echocardiography, computed tomography (CT) or magnetic resonance imaging;
- use of a different mapping catheter or mapping system;
- history of previous BrS substrate ablation.
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06567639
Start Date
April 1 2018
End Date
March 31 2021
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZB
Brussels, Belgium